Elaine Sun compensation by year
HALOZYME THERAPEUTICS Summary Compensation Table · all 3 fiscal years held| Component | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Salary | $395,833 | $494,000 | $44,909 |
| Bonus | $150,000 | $0 | $0 |
| Stock awards | $1,500,269 | $1,155,062 | $0 |
| Option awards | $1,000,008 | $495,009 | $0 |
| Non-equity incentive | $180,352 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $133,399 | $14,271 | $70,831 |
| Total | $3,359,861 | $2,158,342 | $115,740 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: HALOZYME THERAPEUTICS, INC. DEF 14A filed March 24, 2023, accession 0001159036-23-000029, and prior-year filings. Open the filing on EDGAR.
How this page was built: the HALOZYME THERAPEUTICS, INC. filed document, accession 0001159036-23-000029. Every figure is read from that document and cited to the page and table it appears in. Filed March 24, 2023.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 36,496 | $1,467,504 | — |
| PSU | 30,600 | $1,230,426 | — |
| RSU | 14,898 | $599,049 | — |
| PSU | 6,506 | $261,606 | — |
| Option | 59,046 | — | $20.55 |
| Option | 25,642 | — | $49.84 |
Per the Outstanding Equity Awards at Fiscal Year-End table in HALOZYME THERAPEUTICS, INC.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
HALOZYME THERAPEUTICS’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Helen Torley | President and Chief Executive Officer | $9,696,978 |
| Mark Snyder | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary | $3,740,202 |
| Michael LaBarre | Senior Vice President, Chief Technical Officer | $3,123,280 |
| Nicole LaBrosse | Senior Vice President Chief Financial Officer | $2,683,103 |
| Elaine Sun · this page | Former Senior Vice President Chief Financial Officer | $115,740 |
The full HALOZYME THERAPEUTICS compensation record
free company briefThis page is one person within HALOZYME THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the HALOZYME THERAPEUTICS proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are HALOZYME THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.